Overview

Patient Derived Xenograft Models Market is forecasted to value USD 405.32 million by 2028 end and register a CAGR of 16.2% from the forecast period 2022-2028.

FutureWise Market Research has illustrated a report on the Patient Derived Xenograft Models Market. The report provides an in-depth anatomy of market trends affecting its growth. Moreover, it includes intricate insights on profitability graph, market share, SWOT analysis and geographical augmentation of this business. Furthermore, the report provides information on the status of key market players in the competitive landscape analysis of the market.

The Patient Derived Xenograft Models market is projected to achieve significant growth by the end of the forecast period as per the research study conducted by FutureWise research analysts. The report explains that this business is predicted to record a remarkable growth rate over the forecast period. This report provides important information regarding the total valuation that this industry holds presently and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Patient Derived Xenograft Models market are:   
• Crown Bioscience Inc.
• WuXi AppTec 
• Champions Oncology, Inc.
• The Jackson Laboratory
• ONCODESIGN
• Charles River Laboratories International, Inc.
• EPO Berlin-Buch GmBH
• Shanghai LIDE Biotech Co., Ltd.
• Xentech
• Horizon Discovery Group PLC
• JSR Corporation
• Envigo
• Pharmatest Services
• Hera Biolabs 
• Urosphere
(Note: The list of the major players will be updated with the latest market scenario and trends)

Patient Derived Xenograft Models Market Segmentation:

By Type           

• Mice Models
• Rat Models

By Tumor Type

• Gastrointestinal Tumor Models (colorectal, pancreatic, hepatic, and cholangio tumors)
• Gynecological Tumor Models (breast, ovarian, and cervical tumors)
• Respiratory Tumor Models (lung tumors, nasopharyngeal, and bronchial tumors)
• Urological Tumor Models (renal, prostate, and bladder tumors)
• Hematological Tumor Models (leukemia and lymphoma)
• Other Tumor Models (head & neck cancer, sarcoma, and melanoma)

By Application

• Pre-clinical Drug Development and Basic Cancer Research
• Biomarker Analysis

By End User

• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Academic & Research Institutions

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share  
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the market by type, by tumor type, by application, by end user and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key countries — North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization services offered are free of charge with purchase of any license of the report.
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
   1.1. Objectives of the Study 
   1.2. Market Definition 
   1.3. Market Scope 
        1.3.1. Years Considered for the Study
        1.3.2. Market Covered
   1.4. Currency 
   1.5. Limitations 
   1.6. Stakeholders 

2. Research Methodology 
   2.1. Research Data 
        2.1.1. Secondary Data
               2.1.1.1. Key Data from Secondary Sources
        2.1.2. Primary Data
               2.1.2.1. Key Data from Primary Sources
   2.2. Market Size Estimation 
   2.3. Market Breakdown and Data Triangulation 
   2.4. Assumptions for the Study  

3. Executive Summary
   3.1. Market Outlook
   3.2. Segment Outlook
   3.3. Competitive Insights

4. Patient Derived Xenograft Models Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Technology Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Patient Derived Xenograft Models Market Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Patient Derived Xenograft Models Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Technology Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Technology Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Patient Derived Xenograft Models Market, By Type Historical Analysis and Forecast 2022-2028 (USD Million)
   7.1. Gastrointestinal Tumor Models (colorectal, pancreatic, hepatic, and cholangio tumors)
   7.2. Gynecological Tumor Models (breast, ovarian, and cervical tumors)
   7.3. Respiratory Tumor Models (lung tumors, nasopharyngeal, and bronchial tumors)
   7.4. Urological Tumor Models (renal, prostate, and bladder tumors)
   7.5. Hematological Tumor Models (leukemia and lymphoma)
   7.6. Other Tumor Models (head & neck cancer, sarcoma, and melanoma)

8. Patient Derived Xenograft Models Market, By Tumor Type Historical Analysis and Forecast 2022-2028 (USD Million)  
   8.1. Mice Models
   8.2. Rat Models

9. Patient Derived Xenograft Models Market, By Application Historical Analysis and Forecast 2022-2028 (USD Million)  
   9.1. Pre-clinical Drug Development and Basic Cancer Research
   9.2. Biomarker Analysis

10. Patient Derived Xenograft Models Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million)  
    10.1. Pharmaceutical & Biotechnology Companies
    10.2. Contract Research Organizations
    10.3. Academic & Research Institutions

11. North America Patient Derived Xenograft Models Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    11.1. Introduction
    11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          11.2.1. U.S.A
          11.2.2. Canada
          11.2.3. Mexico
    11.3. Market Size (USD Million) Forecast for North America 2022-2028

12. Latin America Patient Derived Xenograft Models Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          12.2.1. Brazil
          12.2.2. Venezuela
          12.2.3. Argentina
          12.2.4. Rest of Latin America
    12.3. Market Size (USD Million) Forecast for Latin America 2022-2028

13. Europe Patient Derived Xenograft Models Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          13.2.1. Germany
          13.2.2. U.K         
          13.2.3. France
          13.2.4. Italy
          13.2.5. Spain
          13.2.6. Russia
          13.2.7. Poland
          13.2.8. Rest of Europe
    13.3. Market Size (USD Million) Forecast for Europe 2022-2028

14. Asia Pacific Patient Derived Xenograft Models Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    14.1. Introduction
    14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          14.2.1. Japan
          14.2.2. China
          14.2.3. India
          14.2.4. Australia and New Zealand
          14.2.5. ASEAN
          14.2.6. Rest of Asia Pacific
    14.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

15. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    15.1. Introduction
    15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          15.2.1. GCC
          15.2.2. Israel
          15.2.3. South Africa
          15.2.4. Rest of MEA
    15.3. Market Size (USD Million) Forecast for MEA 2022-2028

16. Market Share Analysis and Competitive Landscape   
    16.1. Global Landscape - Key Players, Revenue and Presence
    16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    16.3. Global Emerging Companies
    16.4. North America - Market Share Analysis and Key Regional Players
    16.5. Europe - Market Share Analysis and Key Regional Players
    16.6. Asia Pacific - Market Share Analysis and Key Regional Players
    16.7. Global Key Player - Growth Matrix

17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    17.1. Crown Bioscience Inc.
          17.1.1. Company Overview
          17.1.2. Product Portfolio
          17.1.3. SWOT Analysis
          17.1.4. Financial Overview
          17.1.5. Strategic Overview
    17.2. WuXi AppTec
          17.2.1. Company Overview
          17.2.2. Product Portfolio
          17.2.3. SWOT Analysis
          17.2.4. Financial Overview
          17.2.5. Strategic Overview 
    17.3. Champions Oncology, Inc.
          17.3.1. Company Overview
          17.3.2. Product Portfolio
          17.3.3. SWOT Analysis
          17.3.4. Financial Overview
          17.3.5. Strategic Overview
    17.4. The Jackson Laboratory
          17.4.1. Company Overview
          17.4.2. Product Portfolio
          17.4.3. SWOT Analysis
          17.4.4. Financial Overview
          17.4.5. Strategic Overview
    17.5. ONCODESIGN
          17.5.1. Company Overview
          17.5.2. Product Portfolio
          17.5.3. SWOT Analysis
          17.5.4. Financial Overview
          17.5.5. Strategic Overview          
    17.6. Charles River Laboratories International, Inc.
          17.6.1. Company Overview
          17.6.2. Product Portfolio
          17.6.3. SWOT Analysis
          17.6.4. Financial Overview
          17.6.5. Strategic Overview      
    17.7. EPO Berlin-Buch GmBH
          17.7.1. Company Overview
          17.7.2. Product Portfolio
          17.7.3. SWOT Analysis
          17.7.4. Financial Overview
          17.7.5. Strategic Overview
    17.8. Shanghai LIDE Biotech Co., Ltd.
          17.8.1. Company Overview
          17.8.2. Product Portfolio
          17.8.3. SWOT Analysis
          17.8.4. Financial Overview
          17.8.5. Strategic Overview 
    17.9. Xentech 
          17.9.1. Company Overview
          17.9.2. Product Portfolio
          17.9.3. SWOT Analysis
          17.9.4. Financial Overview
          17.9.5. Strategic Overview 
    17.10.Horizon Discovery Group PLC
          17.10.1. Company Overview
          17.10.2. Product Portfolio
          17.10.3. SWOT Analysis
          17.10.4. Financial Overview
          17.10.5. Strategic Overview
    17.11.JSR Corporation
          17.11.1. Company Overview
          17.11.2. Product Portfolio
          17.11.3. SWOT Analysis
          17.11.4. Financial Overview
          17.11.5. Strategic Overview          
    17.12. Envigo
          17.12.1. Company Overview
          17.12.2. Product Portfolio
          17.12.3. SWOT Analysis
          17.12.4. Financial Overview
          17.12.5. Strategic Overview      
    17.13.Pharmatest Services
          17.13.1. Company Overview
          17.13.2. Product Portfolio
          17.13.3. SWOT Analysis
          17.13.4. Financial Overview
          17.13.5. Strategic Overview
    17.14.Hera Biolabs 
          17.14.1. Company Overview
          17.14.2. Product Portfolio
          17.14.3. SWOT Analysis
          17.14.4. Financial Overview
          17.14.5. Strategic Overview
    17.15.Urosphere
          17.15.1. Company Overview
          17.15.2. Product Portfolio
          17.15.3. SWOT Analysis
          17.15.4. Financial Overview
          17.15.5. Strategic Overview

18. Pre and Post COVID-19 Impact
    18.1. Positive influence on the healthcare industry
    18.2. The financial disruption of the manufacturing sector
    18.3. Impact of COVID-19 on emerging companies
    18.4. Significant mandates in the healthcare regulations initiated by administrations
    18.5. The overall economic slowdown of the developing and developed nations

19. FutureWise SME Key Takeaway Points for Client

Tables

Figures